<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871156</url>
  </required_header>
  <id_info>
    <org_study_id>106491</org_study_id>
    <nct_id>NCT00871156</nct_id>
  </id_info>
  <brief_title>Tafenoquine/Chloroquine DDI Study</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DDI study of Tafenoquine and Chloroquine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in
      Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2009</start_date>
  <completion_date type="Actual">August 26, 2009</completion_date>
  <primary_completion_date type="Actual">August 26, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TQ and Chloroquine (Day 2): AUC(0-tau), Cmax and Tmax</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CQ and TQ (Day 3): AUC(0-tau), AUC(0-inf), Cmax, Tmax and t1/2</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs, vital signs, 12-lead ECGs, telemetry, clinical laboratory and ophthalmic assessments</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF, QT, QRS, RR and HR as assessed by 12-lead ECG</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in QTcF</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tafenoquine + Chloroquine vs. Chloroquine alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine, Tafenoquine</intervention_name>
    <description>Chloroquine and Tafenoquine</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>Tafenoquine</other_name>
    <other_name>Chloroquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>Placeob</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and ECGs.
             A subject with a clinical abnormality or laboratory parameters outside the reference
             range may be included only if the Investigator and GSK medical monitor agree that the
             abnormality will not introduce additional risk factors and will not interfere with the
             study procedures.

          -  Male or female between 18 and 55 years of age inclusive, at the time of signing the
             informed consent.

          -  A female subject is eligible to participate if she is of non-childbearing potential or
             of child-bearing potential if has a negative urine pregnancy test at screening and Day
             -1, and agrees to use agreed upon contraception methods until 56 days after stopping
             study drug.

          -  Body weight &gt;=60 kg (132 pounds) and BMI within the range 19-32 kg/m2 (inclusive).

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form

        Exclusion Criteria:

          -  A positive urine drug/alcohol screen at screening or Day -1.

          -  History or regular use of tobacco- or nicotine-containing products within 3 months
             prior to screening.

          -  History of illicit drug abuse within 6 months prior to screening.

          -  History of regular alcohol consumption within 6 months of the study

          -  Subjects who are unwilling to comply with the lifestyle guidelines required.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication.

          -  History of sensitivity to any of the study medications or their components.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Pregnant females as determined by positive urine hCG test at screening or prior to
             dosing.

          -  Lactating females.

          -  Subject is mentally or legally incapacitated.

          -  A positive HIV antibody, Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening.

          -  The subject's systolic blood pressure is outside the range of 90-150mmHg or diastolic
             blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of
             50-100bpm for female subjects and 45-100bpm for male subjects at screening and Day -1.

          -  Cardiac conduction abnormalities as specified inprotocol

          -  Any significant arrhythmia which, in the opinion of the principal investigator and GSK
             medical monitor, will interfere with the safety for the individual subject.

          -  History of angina, ischemic heart disease, myocardial infarction, or clinically
             significant arrhythmia.

          -  History of epilepsy, convulsions or psychological disorders.

          -  History of porphyria.

          -  AST, ALT or alkaline phosphatase &gt;1.5 times the upper limit of normal and/or total
             bilirubin level outside the normal range at screening. A single repeat is allowed for
             eligibility determination.

          -  Documented Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined by a
             quantitative assay of enzyme activity.

          -  History of hemoglobinopathy; or current or past history of methemoglobinemia or
             methemoglobin percentage above the reference range at screening.

          -  History of previous eye surgery involving the retina, Lasik surgery within 90 days, or
             retinal/corneal abnormalities.

          -  Any clinically significant abnormalities on the screening Humphrey 10-2 visual field
             test.

          -  Best corrected visual acuity worse than 0.3 logMAR (20/40 Snellen equivalent) (i.e.,
             20/40 or better vision will be allowed on study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/106491?search=study&amp;study_ids=106491#rs</url>
    <description>Results for study 106491 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, Duparc S, MÃ¶hrle JJ, Webster A, Stinnett S, Hughes A, Griffith S, Beelen AP. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):858-67. doi: 10.1111/bcp.12160.</citation>
    <PMID>23701202</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Drug Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Tafenoquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

